Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

We are building an AI-native operating system for pharma sales and distribution

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process

Gilead posts solid Q1 2026 growth & raises full-year outlook on HIV momentum

Lonza surges on biologics boom

Expands manufacturing push & locks in major growth deals

MilliporeSigma lands exclusive 5-year deal to test Genetix Biotherapeutics gene therapies

The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy

Experts call for easing access to 2mg and 4mg nicotine replacement therapies

With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies

Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%

The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms

Pfizer powers ahead in 2026 with strong Q1 results as pipeline momentum builds

The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook